List view / Grid view

MRC Technology



Antibodies In-Depth Focus 2017

15 March 2017 | By

Lone Friis and David Matthews discuss developability assessment of therapeutic antibodies, and Negin Mokhtari and colleagues explain nanoparticle-mediated enzyme delivery for application in cancer therapy...


The challenges associated with ‘de-risking’ early-stage therapeutic targets

3 December 2015 | By , , ,

The pharmaceutical industry is searching for novel drug targets that could produce the next generation of ‘first-in-class’ therapeutic agents. The challenge for academia is to identify and translate such targets and to provide starting points and confidence in the underlying science. The aim should be to generate evidence that modulation…